To receive your instant CME certificate, you must first "Sign In" or "Sign Up" in the top right corner.
RELEASE DATE: April 1, 2020
EXPIRATION DATE: April 30, 2021
MAXIMUM CREDITS: 1.5 AMA PRA Category 1 Credits™
CLICK HERE TO PROCEED TO PROGRAM
LEARNING METHOD AND MEDIUM
This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 1.5 hours to complete.
Advances in the understanding of the pathophysiology of glaucoma and the recent US Food and Drug Administration approval of new treatment options are challenging traditional treatment paradigms, opening up new opportunities for physicians to improve visual outcomes for their patients with glaucoma. With these newer treatment options come new mechanisms of action, including nitric oxide’s effect on the trabecular meshwork and the subsequent effects on the outflow of aqueous humor. More evidence-based data on the efficacy and safety of these drugs on lowering intraocular pressure are also available, and ophthalmologists who treat glaucoma must stay abreast of these developments in order to optimize patient outcomes. The desired results of this activity are to help ophthalmologists improve their practice strategies by updating them on the treatment and mechanistic effects of newer agents available to treat patients with glaucoma.
This educational activity is intended for ophthalmologists.
Upon completion of this activity, participants will be better able to:
- Describe the downstream signaling effects of nitric oxide and its relation to glaucoma
- Describe the physiologic mechanisms of action for trabecular outflow mediators
- Review recent clinical trial data for agents that mediate trabecular outflow to reduce intraocular pressure
- Design treatment plans for patients with glaucoma that maximize efficacy while minimizing the risk of adverse events that might lead to discontinuation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC. The New York Eye and Ear Infirmary of Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.
AMA CREDIT DESIGNATION STATEMENT
The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing medical education activity is supported through an unrestricted educational grant from Bausch & Lomb Incorporated.
DISCLOSURE POLICY STATEMENT
It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.
Donald L. Budenz, MD, MPH, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Receipt of Intellectual Rights/Patent Holder: Carl Zeiss Meditec, Inc; Consultant/Advisory Board: Bausch & Lomb Incorporated; Nicox; and Santen Inc.
Quang H. Nguyen, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Alcon; Allergan; Bausch & Lomb Incorporated; Glaukos Corporation; Ivantis Inc; Novartis Pharmaceuticals Corporation; and Sight Sciences; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Alcon; Allergan; Bausch & Lomb Incorporated; Glaukos Corporation; Ivantis Inc; Novartis Pharmaceuticals Corporation; and Sight Sciences.
Louis R. Pasquale, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Bausch & Lomb Incorporated; Emerald Bioscience; Eyenovia, Inc; Nicox; and Verily Life Sciences LLC.
Thomas W. Samuelson, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Abbott Medical Optics; AcuMEMS, Inc; Aerie Pharmaceuticals, Inc; Akorn, Inc; Alcon; Allergan; AqueSys, Inc; Bausch & Lomb Incorporated; Beaver-Visitec International; Belkin Laser; Equinox; Glaukos Corporation; Ivantis Inc; Ocuphire Pharma; Polyactiva Pty Ltd; Santen Inc; Shire; Sight Sciences; TearClear; Transcend Medical, Inc; and Valeant; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Belkin Laser; Equinox; Glaukos Corporation; Ivantis Inc; Ocuphire Pharma; Sight Sciences; and TearClear.
NEW YORK EYE AND EAR INFIRMARY OF MOUNT SINAI PEER REVIEW DISCLOSURE
Kateki Vinod, MD, has no relevant commercial relationships to disclose.
EDITORIAL SUPPORT DISCLOSURES
Melissa Carter-Ozhan, MS; Cynthia Tornallyay, RD, MBA, CHCP; Kimberly Corbin, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.
The contributing physicians listed above have attested to the following:
- that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- that all reasonable clinical alternatives will be discussed when making practice recommendations.
This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies
CME Provider Contact Information
For questions about this activity, call 212-870-8127.
TO OBTAIN AMA PRA CATEGORY 1 CREDIT™
To obtain AMA PRA Category 1 Credit™ for this activity, read the material in its entirety and consult referenced sources as necessary. Please take this post test and evaluation online. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Bausch & Lomb Incorporated, or Ophthalmology Times.
This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 195
PROCEED TO ACTIVITY